CAS: 3313-26-6; (Z)-N,N-Dimethyl-9-(3-(4-Methylpiperazin-1-yl)Propylidene)-9H-Thioxanthene-2-Sulfonamide

该化合物是一个合成有机化合物,其特征是其三氧甲基苯核心结构,这是一种多环芳香化合物化合物.该物质具有一个全氟辛烷磺酸功能组,有助于其潜在的生物活动.二甲基氨基氨基生物组和一管状动物的出现表明,该物质可能具有药理特性,可能作为各种生物目标的一种离子体.Z的配置表明,围绕丙基氢链中的双联体,一种特定的几何结构安排,它可能影响该化合物的再活动及其与生物系统的互动.其溶性,稳定性和再活动受到现有功能组的影响,从而成为进一步研究药用化学的候选体.

结构式图片

MSDS等安全信息

欧盟法规

C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2012177593-A1
    优先权日:2009-07-20
    标 题 :Synthesis of dendrimer conjugates
    发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
    权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

    专利号:US-7576211-B2
    优先权日:2004-09-30
    标题 :Synthesis of thienopyridinone compounds and related intermediates
    发明人:DHANOA DALE S; BECKER OREN; NOIMAN SILVIA; CHEN DONGLI; MARANTZ YAEL; SHACHAM SHARON; HEIFETZ ALEXANDER; INBAL BOAZ; BAR-HAIM SHAY; MOHANTY PRADYUMNA; LOBERA MERCEDES; WU LAURENCE
    权利人:EPIX DELAWARE INC
    摘要:The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

    专利号:US-12295961-B2
    优先权日:2009-12-31
    标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
    发明人:DHINGRA OM
    权利人:MARIUS PHARMACEUTICALS INC
    摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

    专利号:US-7309799-B2
    优先权日:2004-06-01
    标 题:Methods for the synthesis of milnacipran and congeners thereof
    发明人:BUCHWALD STEPHEN L; SWAGER TIMOTHY M; RARIY ROMAN V
    权利人:COLLEGIUM PHARMACEUTICAL INC
    摘要:One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof. Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof. The present invention also relates to methods for synthesizing intermediates useful in the non-asymmetric or asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof.

    专利号:US-2012282255-A1
    优先权日:2011-04-07
    标题 :Methods and compositions for the treatment of alcoholism and alcohol dependence
    发明人:PLUCINSKI GREG
    权利人:PLUCINSKI GREG
    摘要:The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated. Accordingly, the methods and compositions of the invention are useful for preventing, treating, diagnosing, or monitoring the progression various alcohol and drug dependency diseases disclosed herein.

    专利号:US-2015352230-A1
    优先权日:2013-01-11
    标 题:Synthesis and isolation of dendrimer based imaging systems
    发明人:MULLEN DOUGLAS GURNETT; BAKER JR JAMES R; BANASZAK HOLL MARK M; HUANG BAOHUA; DOUGHERTY CASEY; BALL JACK
    权利人:UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis and isolation of antibodies conjugated with modular dendrimer nanoparticles. In particular, the present invention is directed to antibodies conjugated with novel modular dendrimer nanoparticles having precise numbers of imaging agents, methods of synthesizing the same, compositions comprising such antibodies conjugated with such modular dendrimer nanoparticles, as well as systems and methods utilizing the conjugates (e.g., in imaging settings) (e.g., in diagnostic and/or therapeutic settings) (e.g., for the delivery of therapeutics, imaging, and/or targeting agents).
    武汉壹加壹生物科技有限公司
    小微企业
    注册号: 91420115MACCW9789M法定代表人:刘明
    注册资本:100万元人民币类型:有限责任公司(自然人投资或控股)
    成立日期:2023-3-17登记机关:武汉市江夏区市场监督管理局
    注册地址: 湖北省武汉市江夏区经济开发区大桥新区邢远长工业园4#楼2楼203
    一般项目:技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广,医学研究和试验发展,生物化工产品技术研发,化工产品销售(不含许可类化工产品),专用化学产品销售(不含危险化学品),合成材料销售,新型催化材料及助剂销售,实验分析仪器销售,技术玻璃制品销售,互联网销售(除销售需要许可的商品),货物进出口,技术进出口,日用百货销售,服装服饰零售,皮革制品销售,化妆品零售,文具用品零售,音响设备销售,五金产品零售,电子产品销售,新材料技术推广服务,新材料技术研发。(除许可业务外,可自主依法经营法律法规非禁止或限制的项目)
    免费会员现货
    http://www.yjybiochem.com
    企业联系电话:166 0273 9303👤
    📞 武汉壹加壹生物科技有限公司 联系方式
    联系人: 向玉田
    手机: 18995604068
    邮箱:673003916@qq.com
    微信 18995604068 | 2140408240
    QQ:2140408240
    ⚠️ 声明: 咨询或交易时请注意风险评估和信息核实,百琢研不参与任何交易。

    地址:湖北省武汉市江夏区经济开发区大桥新区邢远长工业园4#楼2楼203
    常规和库存产品100产品总量: 431
    武汉壹加壹生物科技有限公司logo
    平台资质认证✓营业执照✓
    CAS号:3313-26-6
    中文名:替沃噻吨
    英文名:(Z)-Thiothixene
    纯度:99% HPLC1G/5G/1KG
    产品图片备注:现货
    主打产品,生产工厂、精细化学品、医药中间体、材料中间体
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Thiothixene. 2024 Jul 15. 30(3):200-211. doi: 10.1097/PRA.0000000000000783. 241(6):1205-1212. doi: 10.1007/s00213-024-06554-4. Epub 2024 Feb 20. 46(2):515-521. doi: 10.1007/s11096-023-01693-8. Epub 2024 Feb 5.
    12:20451253221097261. doi: 10.1177/20451253221097261.
    6: Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2.

    合成参考文献


    摘要:Journal of Medicinal Chemistry., 13(17), 1970
    摘要:Trissel, L.A. Handbook on Injectable Drugs. 9th ed. Bethesda, MD. American Society of Health-System Pharmacists' Product Development. 1996., p. 1040
    摘要:Ananth J, Costin A; Am J Psychiatry 134 (6) 689-670 (1977)
    摘要:Yesavage JA et al; Psychopharmacology (Berl) 74 (2): 170-2 (1981)
    摘要:NIH/NLM; ClinicalTrials.Gov. Available from, as of February 2, 2018: https://clinicaltrials.gov/
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知